|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 4,959.80 INR | -2.09% |
|
+4.05% | +29.10% |
| 07-16 | Pfizer suspends sales of Premarin vaginal cream in India, citing supply challenges | RE |
| 07-09 | India's Dr Reddy's says semaglutide shipping disruption to last until at least late October | RE |
| Market Cap | 1,887B 19.59B 17.21B 16B 14.68B 27.59B 28.01B 190B 74.23B 927B 73.54B 71.96B 3,207B | P/E 2027 * |
71.7x | P/E 2028 * | 52.8x |
|---|---|---|---|---|---|
| Enterprise Value | 2,001B 20.78B 18.25B 16.97B 15.57B 29.26B 29.71B 202B 78.74B 984B 78B 76.32B 3,401B | EV / Sales 2027 * |
10.5x | EV / Sales 2028 * | 9.2x |
| Free-Float |
36.66% | Yield 2027 * |
0.61% | Yield 2028 * | 0.69% |
Last Transcript: Torrent Pharmaceuticals Limited
| 1 day | -2.09% | ||
| 1 week | +4.05% | ||
| Current month | +7.29% | ||
| 1 month | +10.13% | ||
| 3 months | +20.51% | ||
| 6 months | +26.30% | ||
| Current year | +29.10% |
| 1 week | 4,769.85 |  | 5,079.25 |
| 1 month | 4,477.65 | | 5,084.85 |
| Current year | 3,724.1 | | 5,084.85 |
| 1 year | 3,480 | | 5,084.85 |
| 3 years | 1,771.35 | | 5,084.85 |
| 5 years | 1,242.5 | | 5,084.85 |
| 10 years | 571.75 | | 5,084.85 |
| Manager | Title | Age | Since |
|---|---|---|---|
Aman Samir Mehta
CEO | Chief Executive Officer | 34 | 31/07/2025 |
Sudhir Menon
DFI | Director of Finance/CFO | - | 31/08/2018 |
Geena Malhotra
CTO | Chief Tech/Sci/R&D Officer | - | 31/01/2026 |
| Director | Title | Age | Since |
|---|---|---|---|
| Chairman | 62 | 29/07/2014 | |
| Director/Board Member | 46 | 07/02/2018 | |
Nayantara Bali
BRD | Director/Board Member | 59 | 06/03/2019 |
| Date | Insider | Type | Main position | Quantity | % Market Cap. | |
|---|---|---|---|---|---|---|
| 29/11/24 | Buy | Chief Operating Officer | 930,144 | 0.2748% |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -2.09% | +4.05% | +41.07% | +155.42% | 19.9B | |
| +0.86% | +1.43% | +48.50% | +160.39% | 1,057B | |
| +1.59% | +4.09% | +55.34% | +53.96% | 624B | |
| +0.95% | +1.91% | +35.91% | +81.14% | 454B | |
| +1.60% | +6.25% | +33.95% | +29.84% | 341B | |
| -0.60% | +1.52% | +35.68% | +39.76% | 297B | |
| -0.14% | +0.60% | +16.17% | +17.53% | 262B | |
| +0.09% | -2.82% | -28.29% | -41.71% | 215B | |
| +1.22% | +2.66% | +21.87% | +59.73% | 201B | |
| -1.18% | -3.70% | +14.23% | +66.51% | 162B | |
| Average | +0.12% | +1.26% | +27.44% | +62.26% | 363.39B | |
| Weighted average by Cap. | +0.53% | +1.91% | +35.76% | +78.04% |
| 2027 * | 2028 * | |
|---|---|---|
| Net sales | 190B 1.98B 1.74B 1.62B 1.48B 2.79B 2.83B 19.18B 7.49B 93.64B 7.42B 7.26B 324B | 214B 2.22B 1.95B 1.82B 1.67B 3.13B 3.18B 21.56B 8.42B 105B 8.34B 8.16B 364B |
| Net income | 24.86B 258M 227M 211M 194M 364M 369M 2.5B 978M 12.22B 969M 948M 42.26B | 33.98B 353M 310M 288M 264M 497M 505M 3.42B 1.34B 16.7B 1.32B 1.3B 57.76B |
| Net Debt | 114B 1.19B 1.04B 970M 890M 1.67B 1.7B 11.52B 4.5B 56.24B 4.46B 4.36B 194B | 82.03B 852M 748M 696M 638M 1.2B 1.22B 8.26B 3.23B 40.33B 3.2B 3.13B 139B |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24/07/26 | ₹4,959.80 | -2.09% | 5,220 |
| 23/07/26 | ₹5,065.80 | +0.60% | 6,972 |
| 22/07/26 | ₹5,035.40 | -0.07% | 11,022 |
| 21/07/26 | ₹5,038.75 | +0.71% | 9,443 |
| 20/07/26 | ₹5,003.25 | +4.96% | 32,658 |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Quarterly revenue - Rate of surprise
- Stock Market
- Stocks
- TORNTPHARM Stock
Select your edition
All financial news and data tailored to specific country editions
